Since 2021, China National Medical Products Administration (NMPA) has implemented the Cosmetic Supervision and Administration Regulation (CSAR) and a series of subsidiary regulations, which have reconstructed the entire cosmetics regulatory system. The new regulatory focus is on a combination of pre-market approval and post-market surveillance, marking a shift from the previous emphasis on pre-market approval.

In comparing China’s new regulatory system to that of EU, there exist both similarities and differences. European companies or those already involved in the cosmetics market in Europe need to consider the distinctions before introducing their products to the Chinese market. In this upcoming speech, Hedy He, a regulatory analyst from ChemLinked, will delve into these variances, covering fundamental regulatory information, pre-market requirements, post-market surveillance, and company responsibilities.